Shawn Gremminger

Employers are facing higher costs and employees higher premiums as 340B’s growth drives lost rebates and rising drug prices.

Expert emphasizes the need for stronger transparency and patient definitions in the 340B program.

An expert shares how 340B puts independent pharmacies at a competitive disadvantage.